Purpose: To evaluate if there are differences in toxicity and efficacy between different Bacillus Calmette-Guerin (BCG) stains used for intravesical immunotherapy in patients with non-muscle invasive bladder cancer. Methods: We retrospectively analysed a group of 844 patients who received TICE, RIVM and Moreau BCG strains. The allocation of the strain to each patient was random, stemming from differences in supply and distribution. The patients were analysed in terms of toxicity, recurrence-free (RFS), progression-free (PFS), cancer-specific (CSS) and overall survival (OS). Results: In the survival analysis, statistical significance was not reached in any tumour group for any clinical event. TICE caused more local and mild adverse effects and severe complications were mainly associated with RIVM strain. In a group in which the strain was changed during the course of the therapy, significantly more severe complications were observed and, in most of these cases, complications appeared right after the strain change. Conclusions: There were no differences in terms of RFS, PFS, CSS and OS after use of TICE, RIVM and Moreau strains. The complication profile differed statistically between used strains with TICE causing mostly mild complications. Also, strain change during the therapy course was associated with the increased risk of moderate to severe toxicity occurrence.

Keywords:
Non-muscle-invasive bladder cancer, Bacillus Calmette-Guerin, Recurrence, Progression, Strain
1.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30.
2.
Ritz N, Hanekom WA, Robins-Browne R, Britton WJ, Curtis N: Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev 2008; 32: 821–841.
3.
Herr HW, Morales A: History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008; 179: 53–56.
4.
Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, Valenti P, Dos Santos S, Duthoy S, Lacroix C, Garcia-Pelayo C, Inwald JK, Golby P, Garcia JN, Hewinson RG, Behr MA, Quail MA, Churcher C, Barrell BG, Parkhill J, Cole ST: Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A 2007; 104: 5596–5601.
5.
Behr MA: BCG – different strains, different vaccines? Lancet Infect Dis 2002; 2: 86–92.
6.
Fellows GJ, Parmar MK, Grigor KM, Hall RR, Heal MR, Wallace DM: Marker tumour response to evans and pasteur bacille Calmette-Guerin in multiple recurrent pTa/pT1 bladder tumours: report from the medical research council subgroup on superficial bladder cancer (urological cancer working party). Br J Urol 1994; 73: 639–644.
7.
Mukherjee A, Persad R, Smith PJ: Intravesical BCG treatment for superficial bladder cancer: long-term results using two different strains of BCG. Br J Urol 1992; 69: 147–150.
8.
Rentsch CA, Birkhauser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, Lagranderie M, Marchal G, Orgeur M, Bouchier C, Bachmann A, Ingersoll MA, Brosch R, Albert ML, Thalmann GN: Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol 2014; 66: 677–688.
9.
Sengiku A, Ito M, Miyazaki Y, Sawazaki H, Takahashi T, Ogura K: A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol 2013; 190: 50–54.
10.
Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ: Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guerin-Tice versus bacillus Calmette-Guerin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Semin Urol Oncol 1996; 14: 10–16.
11.
Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 2000; 163: 1124–1129.
12.
Saint F, Irani J, Patard JJ, Salomon L, Hoznek A, Zammattio S, Debois H, Abbou CC, Chopin DK: Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer. Urology 2001; 57: 883–888.
13.
Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, Small PM: Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999; 284: 1520–1523.
14.
Noon AP, Catto JW: Bladder cancer in 2012: challenging current paradigms. Nature Rev Urol 2013; 10: 67–68.
15.
Boehm BE, Cornell JE, Wang H, Mukherjee N, Oppenheimer JS, Svatek RS: Efficacy of bacillus Calmette-Guerin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis. J Urol 2017; 198: 503–510.
16.
Vegt PD, van der Meijden AP, Sylvester R, Brausi M, Holtl W, de Balincourt C: Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. J Urol 1997; 157: 1246–1249.
17.
Sylvester RJ, van der MA, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964–1970.
18.
Vegt PD, Witjes JA, Witjes WP, Doesburg WH, Debruyne FM, van der Meijden AP: A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 1995; 153: 929–933.
19.
Witjes JA, Dalbagni G, Karnes RJ, Shariat S, Joniau S, Palou J, Serretta V, Larre S, di Stasi S, Colombo R, Babjuk M, Malmstrom PU, Malats N, Irani J, Baniel J, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Pisano F, Gontero P, Sylvester R: The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. Urol Oncol 2016; 34: 484.e419–e484.e425.
20.
van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV, Group EG-UTC: Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer Genito-Urinary group phase III trial. Eur Urol 2003; 44: 429–434.
21.
Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Turkeri L, Marreaud S, Collette S, Oosterlinck W: Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014; 65: 69–76.
22.
Brosman SA: Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1982; 128: 27–30.
23.
Ikeda N, Honda I, Yano I, Koyama A, Toida I: Bacillus calmette-guerin Tokyo172 substrain for superficial bladder cancer: characterization and antitumor effect. J Urol 2005; 173: 1507–1512.
24.
Inamoto T, Ubai T, Nishida T, Fujisue Y, Katsuoka Y, Azuma H: Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guerin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison. Urol Ann 2013; 5: 7–12.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.